Repression of EZH2 in tumor-infiltrating Treg cells thus promote pro-inflammatory signaling and enhance recruitment of CD8+ and CD4+ effector T cells, ultimately leading to tumor regression [324]. The gene discussed is CD4; the disease is neoplasm.